1. Home
  2. RMCF vs HCWB Comparison

RMCF vs HCWB Comparison

Compare RMCF & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocky Mountain Chocolate Factory Inc.

RMCF

Rocky Mountain Chocolate Factory Inc.

HOLD

Current Price

$1.50

Market Cap

14.9M

ML Signal

HOLD

HCWB

HCW Biologics Inc.

HOLD

Current Price

$1.08

Market Cap

14.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCF
HCWB
Founded
1981
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9M
14.8M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
RMCF
HCWB
Price
$1.50
$1.08
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$35.00
AVG Volume (30 Days)
39.4K
2.6M
Earning Date
06-16-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
34.88
N/A
EPS
N/A
0.37
Revenue
$30,432,352.00
$4,099,750.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.95
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$0.25
52 Week High
$2.99
$7.35

Technical Indicators

Market Signals
Indicator
RMCF
HCWB
Relative Strength Index (RSI) 27.12 43.71
Support Level $1.50 $1.03
Resistance Level $1.82 $1.26
Average True Range (ATR) 0.13 0.19
MACD -0.01 -0.12
Stochastic Oscillator 9.62 4.53

Price Performance

Historical Comparison
RMCF
HCWB

About RMCF Rocky Mountain Chocolate Factory Inc.

Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Share on Social Networks: